Healx raises €50.4M Series B round
16 October 2019· Cambridge, United Kingdom· health, biotech, ai, drug_discovery, pure_software, b2b
The funds will be used to develop the company's therapeutic pipeline and to launch its global Rare Treatment Accelerator programme. The investment will also be used to build a clinical-stage portfolio for rare diseases, including treatments for Fragile X syndrome.
Investors
LeadAtomico
Also participating
Balderton Capitalbtov PartnersAmadeus Capital PartnersIntel CapitalGlobal BrainJonathan Milner
About Healx
Stage
Series C
Headquarters
Cambridge, United Kingdom
Founded
2014
Team Size
51–200
Sectors
healthbiotechaidrug_discoverypure_softwareb2b